SpringerLink
Log in

Comparison of overall survival between the early use and delayed use of Trastuzumab therapy groups: a retrospective analysis of 128 patients with HER-2-positive advanced breast cancer

  • Original Paper
  • Published:
Medical Oncology Aims and scope Submit manuscript

Abstract

Trastuzumab has been the standard treatment in first-line treatment of HER-2-positive advanced breast cancer (H2ABC). This study explored whether the delayed and repeated use of trastuzumab could influence overall survival (OS). A total of 128 patients with H2ABC who had received at least one line of trastuzumab-based regimens were included. The primary endpoint was OS defined as from the date of first diagnosis of H2ABC to death. The median OS of initiating trastuzumab in first-line group (n = 56), in the second-line group (n = 32), and the third- or more-line group (n = 40) was 40.6 m, 39.5 m, and 38 m, respectively (P = 0.867). For patients who had received over one line of trastuzumab (n = 46), the median OS was 44 m, and for those receiving only one line (n = 67), it was 27.6 m (P = 0.059). The delayed use of trastuzumab has no negative effect on the OS of patients with H2ABC. There is a trend of improved OS over the repeated use of trastuzumab.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–82.

    Article  PubMed  CAS  Google Scholar 

  2. Janes PW, Daly RJ, deFazio A, Sutherland RL. Activation of the Ras signaling pathway in human breast cancer cells overexpressing erbB-2. Oncogene. 1994;9:3601–8.

    PubMed  CAS  Google Scholar 

  3. Burstein HJ. The distinctive nature of HER2-positive breast cancer. N Engl J Med. 2005;353:1652–4.

    Article  PubMed  CAS  Google Scholar 

  4. Goldhirsch A, Coates AS, Gelber RD, Glick JH, Thürlimann B, Senn HJ. St Gallen expert panel members: first—select the target: Better choice of adjuvant treatments for breast cancer patients. Ann Oncol. 2006;17:1772–6.

    Article  PubMed  CAS  Google Scholar 

  5. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783–92.

    Article  PubMed  CAS  Google Scholar 

  6. Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(3):719–26.

    Article  PubMed  CAS  Google Scholar 

  7. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, et al. Herceptin adjuvant (HERA) trial study team. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med. 2005;353(16):1659–72.

    Google Scholar 

  8. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005;353(16):1673–84.

    Article  PubMed  CAS  Google Scholar 

  9. Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr, Ewer M, Keefe D, Shannon RP, Swain SM, Brown A, Fehrenbacher L, et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer. NSABP B-31. J Clin Onco. 2005;l23(31):7811–19.

    Google Scholar 

  10. Tripathy D, Slamon DJ, Cobleigh M, Arnold A, Saleh M, Mortimer JE, Murphy M, Stewart SJ. Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression. J Clin Oncol. 2004;22:1063–70.

    Article  PubMed  CAS  Google Scholar 

  11. Cancello G, Montagna E, D’Agostino D, Giuliano M, Giordano A, Di Lorenzo G, Plaitano M, De Placido S, De Laurentiis M. Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. Breast Cancer Res. 2008;10(4):R60.

    Article  PubMed  Google Scholar 

  12. Montemurro F, Donadio M, Clavarezza M, Redana S, Jacomuzzi ME, Valabrega G, Danese S, Vietti-Ramus G, Durando A, Venturini M, et al. Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy. Oncologist. 2006;11:318–24.

    Article  PubMed  CAS  Google Scholar 

  13. Extra J-M, Antoine EC, Vincent-Salomon A, Delozier T, Kerbrat P, Bethune-Volters A, Guastalla J-P, Spielmann M, Mauriac L, Misset J-L, et al. Efficacy of Trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational hermine study. Oncologist. 2010;15:799–09

    Google Scholar 

  14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.

    Article  PubMed  CAS  Google Scholar 

  15. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13(3):176–81.

    Google Scholar 

  16. Cancello G, Emilia Montagna, Diego D’Agostino, Mario Giuliano, Antonio Giordano, Giuseppe Di Lorenzo, Monica Plaitano, Sabino De Placido, Michele De Laurentiis. Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. Breast Cancer Res. 2008;10(4):2–8.

  17. Minckwitz G, du Bois A, Schmidt M, Maass N, Cufer T, de Jongh FE, Maartense E, Zielinski C, Kaufmann M, Bauer W, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03–05 study. J Clin Oncol. 2009;27:1999–2006.

    Article  Google Scholar 

  18. Stemmler HJ, Kahlert S, Siekiera W, Untch M, Heinrich B, Heinemann V. Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC). Onkologie. 2005;28:582–6.

    Article  PubMed  CAS  Google Scholar 

  19. Marty M, Cognetti F, Maraninchi D, Snyder R, Mauriac L, Tubiana-Hulin M, Chan S, Grimes D, Antón A, Lluch A, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol. 2005;23:4265–74.

    Article  PubMed  CAS  Google Scholar 

  20. Robert N, Leyland-Jones B, Asmar L, Belt R, Ilegbodu D, Loesch D, Raju R, Valentine E, Sayre R, Cobleigh M, et al. Randomized Phase III Study of Trastuzumab, Paclitaxel and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2006;24:2786–92.

    Article  PubMed  CAS  Google Scholar 

  21. Bartsch R, Wenzel C, Hussian D, Pluschnig U, Sevelda U, Koestler W, Altorjai G, Locker GJ, Mader R, Zielinski CC, Steger GG. Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study. BMC Cancer. 2006; 6:63.

    Google Scholar 

  22. Fountzilas G, Razis E, Tsavdaridis D, Karina M, Labropoulos S, Christodoulou C, Mavroudis D, Gogas H, Georgoulias V, Skarlos D. Continuation of trastuzumab beyond disease progression is feasible and safe in patients with metastatic breast cancer: a retrospective analysis of 80 cases by the Hellenic Cooperative Oncology Group. Clin Breast Cancer. 2003;4:120–5.

    Article  PubMed  CAS  Google Scholar 

  23. Gelmon KA, Mackey J, Verma S, Gertler SZ, Bangemann N, Klimo P, Schneeweiss A, Bremer K, Soulieres D, Tonkin K, et al. Use of trastuzumab beyond disease progression: observations from a retrospective review of case histories. Clin Breast Cancer. 2004;5:52–8.

    Article  PubMed  CAS  Google Scholar 

  24. Morabito A, Longo R, Gattuso D, Carillio G, Massaccesi C, Mariani L, Bonginelli P, Amici S, De Sio L, Fanelli M, et al. Trastuzumab in combination with gemcitabine and vinorelbine as second-line therapy for HER-2/neu overexpressing metastatic breast cancer. Oncol Rep. 2006;16:393–8.

    PubMed  CAS  Google Scholar 

  25. Bartsch R, Wenzel C, Altorjai G, Pluschnig U, Rudas M, Mader RM, Gnant M, Zielinski CC, Steger GG. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol. 2007;25:3853–8.

    Article  PubMed  CAS  Google Scholar 

  26. García-Sáenz JA, Martín M, Puente J, López-Tarruella S, Casado A, Moreno F, Grande E, Díaz-Rubio E. Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer. Clin Breast Cancer. 2005;6:325–9.

    Google Scholar 

  27. Jahanzeb M. Continuing trastuzumab beyond progression. J Clin Oncol. 2009;27(12):1935–7.

    Google Scholar 

  28. Seidman A, Hudis C, Pierri MK, Shak S, Paton V, Ashby M, Murphy M, Stewart SJ, Keefe D. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol. 2002;20(5):1215–21.

    Article  PubMed  CAS  Google Scholar 

  29. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol. 1999;17:2639–48.

    PubMed  CAS  Google Scholar 

  30. Chien KR. Stress pathways and heart failure. Cell. 1995;98:555–8.

    Article  Google Scholar 

  31. Guarneri V, Lenihan DJ, Valero V, Durand JB, Broglio K, Hess KR, Michaud LB, Gonzalez-Angulo AM, Hortobagyi GN, Esteva FJ. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: The M.D. Anderson Cancer Center experience. J Clin Oncol. 2006;24:4107–15.

    Article  PubMed  CAS  Google Scholar 

  32. Redana S, Donadio M, Nole F, Jacomuzzi ME, Beano A, Martinello R, Sapino A, Viale G, Aglietta M, Montemurro F. Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison. BMC Cancer. 2010;10:28.

    Article  PubMed  Google Scholar 

  33. Yardley DA, Burris HA 3rd, Hanson S, Greco FA, Spigel DR, Barton J, Hainsworth JD. Weekly Gemcitabine and Trastuzumab in the Treatment of Patients With HER2-Overexpressing Metastatic Breast Cancer. Clin Breast Cancer. 2009;9:178–83.

    Article  PubMed  CAS  Google Scholar 

  34. http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=675276&version=HealthProfessional&protocolsearchid=8293160.

  35. http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=594764&version=HealthProfessional&protocolsearchid=8293160.

  36. http://www.cancer.gov/search/ViewClinicalTrials.aspx?cdrid=637198&version=HealthProfessional&protocolsearchid=8293160.

  37. Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, Chan S, Jagiello-Gruszfeld A, Kaufman B, Crown J, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008;112:533–43.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgment

This study was funded by the National “Eleventh Five” technology major project (2008ZX09312-002) and the Research Award Fund for Outstanding Young researchers in Sun Yat-sen Cancer Center. We thank lecturer Yu-Wen Du from medical college of Sun Yat-Sen University for her generous help in manuscript revision.

Conflicts of interest

All authors state that they have no conflicts of interest and potential conflicts.

Author information

Authors and Affiliations

  1. State Key Laboratory of Oncology in Southern China & Department of Medical Oncology, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, 510060, Guangzhou, Guangdong, People’s Republic of China

    Yan-**a Shi, Yu-Ting Tan, Zhong-Yu Yuan, Shu-Sen Wang, Rou-Jun Peng, **n An, Ye Cao, Ying **, **u-Yu Cai, Yue-Li Sun, **ao-Yu Teng & Dong-Geng Liu

Authors
  1. Yan-**a Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yu-Ting Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhong-Yu Yuan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shu-Sen Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rou-Jun Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. **n An
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ye Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ying **
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. **u-Yu Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Yue-Li Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. **ao-Yu Teng
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Dong-Geng Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dong-Geng Liu.

Additional information

Yan-**a Shi and Yu-Ting Tan contributed equally to this work.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shi, YX., Tan, YT., Yuan, ZY. et al. Comparison of overall survival between the early use and delayed use of Trastuzumab therapy groups: a retrospective analysis of 128 patients with HER-2-positive advanced breast cancer. Med Oncol 29, 39–47 (2012). https://doi.org/10.1007/s12032-010-9798-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12032-010-9798-3

Keywords

Search

Navigation